✦ LIBER ✦

Plasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifen

✍ Scribed by G. Anker; P. E. Lonning; P. M. Ueland; H. Refsum; E. A. Lien

Publisher: John Wiley and Sons
Year: 2006
Tongue: French
Weight: 488 KB
Volume: 60
Category: Article
ISSN: 0020-7136
DOI: 10.1002/ijc.2910600316

No coin nor oath required. For personal study only.

✦ Synopsis

Long-term treatment of breast-cancer patients with the anti-oestrogen tamoxifen has been found to be associated with reduced cardiovascular mortality. Plasma homocysteine is an independent risk factor for atherosclerotic disease, and its level is determined by folate and cobalamin status, and possibly also by oestrogen status. We measured the effect of tamoxifen on plasma homocysteine, serum cholesterol, serum cobalamin and serum and erythrocyte folate in 31 post-menopausal women with breast cancer. The plasma homocysteine level was decreased by a mean value of 29.8% after 9-12 months and by 24.5% after 13-16 months of treatment. Tamoxifen suppressed serum cholesterol by mean values varying between 7.2% and 17.6% after 3 to 19 months of treatment. There was no correlation between changes in plasma homocysteine and serum cholesterol. These findings suggest that the homocysteinelowering effect of tamoxifen may contribute to the reduction of cardiovascular mortality observed in patients on adjuvant therapy with tamoxifen.

📜 SIMILAR VOLUMES

Effect of tamoxifen on plasma lipids and

Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer

✍ Muthusamy Thangaraju; Kalyanam Kumar; Rengasamy Gandhirajan; Panchanatham Sachda 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 2 views

The association of plasma androgen level

The association of plasma androgen levels with breast, ovarian and endometrial cancer risk factors among postmenopausal women

✍ Kim N. Danforth; A. Heather Eliassen; Shelley S. Tworoger; Stacey A. Missmer; Ro 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 143 KB 👁 1 views

## Abstract Although androgens may play an etiologic role in breast, ovarian and endometrial cancers, little is known about factors that influence circulating androgen levels. We conducted a cross‐sectional analysis among 646 postmenopausal women in the Nurses' Health Study to examine associations

The distribution of oestradiol in plasma

The distribution of oestradiol in plasma from postmenopausal women with or without breast cancer: Relationships with metabolic clearance rates of oestradiol

✍ M. J. Reed; P. A. Beranek; R. W. Cheng; M. W. Ghilchik; V. H. T. James 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 French ⚖ 429 KB 👁 1 views

## Abstract The distribution of oestradiol in plasma from post‐menopausal women with or without breast cancer has been measured and related to the metabolic clearance rates of oestradiol (MCR‐E2). All measurements were carried out preoperatively. No difference in the free fraction of oestradiol was

Comparison of anastrozole versus tamoxif

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer : The pre-operative “Arimidex” compared to Tamoxifen (PROACT) trial

✍ Luigi Cataliotti; Aman U. Buzdar; Shinzaburo Noguchi; Jose Bines; Yuichi Takatsu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

## Abstract ## BACKGROUND The Pre‐Operative “Arimidex” Compared to Tamoxifen (PROACT) study was a randomized, multicenter study comparing anastrozole with tamoxifen as a preoperative treatment of postmenopausal women with large, operable (T2/3, N0‐2, M0), or potentially operable (T4b, N0‐2, M0) br

Anastrozole alone or in combination with

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer : Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses

✍ The ATAC (Arimidex; Tamoxifen Alone or in Combination) Trialists' Group 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 2 views

## Abstract ## BACKGROUND The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow‐up, 33 months) demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer, anastrozole was superior to tamoxifen in terms of d

The effect of endocrine therapy with med

The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer

✍ M. J. Reed; A. Christodoulides; R. Koistinen; M. Seppälä; J. D. Teale; M. W. Ghi 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 French ⚖ 413 KB 👁 1 views